IN2014KN02335A - - Google Patents
Info
- Publication number
- IN2014KN02335A IN2014KN02335A IN2335KON2014A IN2014KN02335A IN 2014KN02335 A IN2014KN02335 A IN 2014KN02335A IN 2335KON2014 A IN2335KON2014 A IN 2335KON2014A IN 2014KN02335 A IN2014KN02335 A IN 2014KN02335A
- Authority
- IN
- India
- Prior art keywords
- patient
- risk
- reducing
- acting insulin
- therapeutically effective
- Prior art date
Links
- 108010092217 Long-Acting Insulin Proteins 0.000 abstract 3
- 102000016261 Long-Acting Insulin Human genes 0.000 abstract 3
- 229940100066 Long-acting insulin Drugs 0.000 abstract 3
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 108010057186 Insulin Glargine Proteins 0.000 abstract 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 abstract 1
- 229960002869 insulin glargine Drugs 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261616768P | 2012-03-28 | 2012-03-28 | |
| US201261619641P | 2012-04-03 | 2012-04-03 | |
| US201261624598P | 2012-04-16 | 2012-04-16 | |
| US201261645909P | 2012-05-11 | 2012-05-11 | |
| US201261701911P | 2012-09-17 | 2012-09-17 | |
| PCT/EP2013/056661 WO2013144273A1 (en) | 2012-03-28 | 2013-03-28 | Basal insulin therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014KN02335A true IN2014KN02335A (enExample) | 2015-05-01 |
Family
ID=48044781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2335KON2014 IN2014KN02335A (enExample) | 2012-03-28 | 2013-03-28 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150065421A1 (enExample) |
| EP (1) | EP2830650A1 (enExample) |
| JP (1) | JP2015512908A (enExample) |
| KR (1) | KR20150001757A (enExample) |
| CN (1) | CN104334183A (enExample) |
| AU (1) | AU2013241776B2 (enExample) |
| CA (1) | CA2865823A1 (enExample) |
| HK (1) | HK1201155A1 (enExample) |
| IN (1) | IN2014KN02335A (enExample) |
| MX (1) | MX2014011687A (enExample) |
| RU (1) | RU2014143271A (enExample) |
| SG (1) | SG11201405433XA (enExample) |
| WO (1) | WO2013144273A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017108943A1 (en) * | 2015-12-23 | 2017-06-29 | Sanofi-Aventis Deutschland Gmbh | Cardiac metabolic effect of lantus |
| MA46890A (fr) | 2016-11-28 | 2021-04-28 | Novo Nordisk As | Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme |
| EP3544683A1 (en) | 2016-11-28 | 2019-10-02 | Novo Nordisk A/S | Insulin degludec in cardiovascular conditions |
| WO2018096164A1 (en) * | 2016-11-28 | 2018-05-31 | Novo Nordisk A/S | Insulin degludec for treating diabetes |
| US20190357853A1 (en) * | 2018-05-24 | 2019-11-28 | Lizheng Shi | Diabetes risk engine and methods thereof for predicting diabetes progression and mortality |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0309154D0 (en) * | 2003-01-14 | 2003-05-28 | Aventis Pharma Inc | Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia |
| PH12012502524A1 (en) * | 2010-06-24 | 2014-02-10 | Boehringer Ingelheim Int | Diabetes therapy |
-
2013
- 2013-03-28 IN IN2335KON2014 patent/IN2014KN02335A/en unknown
- 2013-03-28 JP JP2015502348A patent/JP2015512908A/ja not_active Ceased
- 2013-03-28 CA CA2865823A patent/CA2865823A1/en not_active Abandoned
- 2013-03-28 CN CN201380028029.4A patent/CN104334183A/zh active Pending
- 2013-03-28 WO PCT/EP2013/056661 patent/WO2013144273A1/en not_active Ceased
- 2013-03-28 US US14/387,791 patent/US20150065421A1/en not_active Abandoned
- 2013-03-28 EP EP13713425.0A patent/EP2830650A1/en not_active Withdrawn
- 2013-03-28 AU AU2013241776A patent/AU2013241776B2/en not_active Expired - Fee Related
- 2013-03-28 KR KR20147028987A patent/KR20150001757A/ko not_active Withdrawn
- 2013-03-28 RU RU2014143271A patent/RU2014143271A/ru not_active Application Discontinuation
- 2013-03-28 SG SG11201405433XA patent/SG11201405433XA/en unknown
- 2013-03-28 HK HK15101611.0A patent/HK1201155A1/xx unknown
- 2013-03-28 MX MX2014011687A patent/MX2014011687A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150001757A (ko) | 2015-01-06 |
| RU2014143271A (ru) | 2016-05-20 |
| SG11201405433XA (en) | 2014-10-30 |
| WO2013144273A1 (en) | 2013-10-03 |
| AU2013241776A1 (en) | 2014-10-16 |
| CN104334183A (zh) | 2015-02-04 |
| EP2830650A1 (en) | 2015-02-04 |
| HK1201155A1 (en) | 2015-08-28 |
| US20150065421A1 (en) | 2015-03-05 |
| JP2015512908A (ja) | 2015-04-30 |
| MX2014011687A (es) | 2015-05-11 |
| AU2013241776B2 (en) | 2017-11-02 |
| CA2865823A1 (en) | 2013-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY167234A (en) | Novel glucagon analogues | |
| PH12012502524A1 (en) | Diabetes therapy | |
| MX2020010693A (es) | Uso de peptidos glp-1 de accion prolongada. | |
| CL2013003454A1 (es) | Composicion farmacéutica para prevenir o tratar diabetes que comprende un conjugado de insulina de accion prolongada y un conjugado de peptido insulinotropico de accion prolongada. | |
| MX356728B (es) | Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2. | |
| MY174727A (en) | Stable, protracted glp-1/glucagon receptor co-agonists for medical use | |
| PH12014501702A1 (en) | Imidazopyrrolidinone compounds | |
| PH12014501561A1 (en) | Therapeutically active compounds and their methods of use | |
| MX2013011175A (es) | Analogos de glucagon novedosos. | |
| EA201590058A1 (ru) | Аналоги глюкагона | |
| IN2015DN00450A (enExample) | ||
| MX366090B (es) | Combinación farmacéutica para usarse en mejorar la tolerancia a la glucosa en pacientes que padecen diabetes de tipo 2. | |
| MX363507B (es) | Metodos para administrar óxido nítrico a la sangre arterial o arterializada. | |
| MX2015012322A (es) | Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes. | |
| WO2014153385A3 (en) | Methods of treating metabolic disorders | |
| HK1201155A1 (en) | Basal insulin therapy | |
| WO2013083826A3 (en) | Glp-1 agonists | |
| MX2016007682A (es) | Composicion farmaceutica que comprende ivabradina amorfa. | |
| WO2014018763A3 (en) | Method of treating type i diabetes using apolipoprotein aiv | |
| MX359171B (es) | Tratamiento para diabetes tipo i y tipo ii. | |
| PH12014502497A1 (en) | New treatments of hepatitis c virus infection | |
| UA111785C2 (uk) | Композиція для лікування бородавок та спосіб лікування бородавок | |
| GB201217635D0 (en) | Use of short term insulin treatment to restore pancreatic function in type 2 diabetic patients who have become refractory through oral hypolgycaemic agents | |
| UA79052U (ru) | Способ иммунокоррекции при обострениях хронического бронхита у больных с инсулинорезистентностью | |
| UA69222U (ru) | Способ рефлексотерапии больных с отдаленными последствиями черепно-мозговой травмы |